miR-155 regulative network in FLT3 mutated acute myeloid leukemia

被引:22
|
作者
Salemi, Domenico [1 ]
Cammarata, Giuseppe [2 ]
Agueli, Cecilia [1 ]
Augugliaro, Luigi [3 ]
Corrado, Chiara [5 ]
Bica, Maria Grazia [1 ]
Raimondo, Stefania [5 ]
Marfia, Anna [1 ]
Randazzo, Valentina [1 ]
Dragotto, Paola [1 ]
Di Raimondo, Francesco [4 ]
Alessandro, Riccardo [5 ]
Fabbiano, Francesco [1 ]
Santoro, Alessandra [1 ]
机构
[1] AO Osped Riuniti Villa Sofia Cervello, Div Ematol Con UTMO, Palermo, Italy
[2] IBIM CNR, Palermo, Italy
[3] Univ Palermo, Dipartimento Sci Stat & Matemat Silvio Vianelli, I-90133 Palermo, Italy
[4] PO Ferrarotto Catania, Div Ematol, Catania, Italy
[5] Dipartimento Biopatol & Biotecnol Med & Forensi, Sez Biol & Genet, Palermo, Italy
关键词
Network; MicroRNA; AML; INTERNAL TANDEM DUPLICATION; MICRORNA EXPRESSION PROFILES; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CELL-GROWTH; DIFFERENTIATION; TARGET; IDENTIFICATION; PROLIFERATION; SUPPRESSION;
D O I
10.1016/j.leukres.2015.04.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Acute myeloid leukemia (AML) represents a heterogeneous disorder with recurrent chromosomal alterations and molecular abnormalities. Among AML with normal karyotype (NK-AML) FLT3 activating mutation, internal tandem duplication (FLT3-ITD), is present in about 30% of patients, conferring unfavorable outcome. Our previous data demonstrated specific up-regulation of miR-155 in FLT3-ITD+ AML. miR-155 is known to be directly implicated in normal hematopoiesis and in some pathologies such as myeloid hyperplasia and acute lymphoblastic leukemia. Methods and results: To investigate about the potential influence of miR-155 de-regulation in FLT3-mutated AML we generated a transcription factors regulatory network and combined this with data from multiple sources that predict miR-155 interactions. From these analyses, we derived a sub-network, called "miR-155 module" that describes functional relationship among miR-155 and transcription factorsin FLT3-mutated AML. We found that "miR-155 module" is characterized by the presence of six transcription factors as central hubs: four miR-155 regulators (JUN, RUNX1, FOSb, JUNB) and two targets of miR-155 (SPI1, CEBPB) all known to be "master" genes of myelopoiesis. We found, in FLT3-mutated AML, a significant down-regulation of miR-155 target genes CEBPB and SPI1 and up-regulation of miR-155 regulator genes JUN and RUNX1. We also showed that PKC412-related FLT3 inhibition, in MV4-11 cell line, causes down-regulation of miR-155 and increased level of mRNA and protein of miR-155 target SPI1. We showed in experiments of miR-155 mimic in K562 cell line, a high increase of miR-155 and an inverse correlation with the mRNA levels of its targets SPI1 and CEBPB. Moreover silencing of miR-155 in primary AMLs causes mRNA up-regulation of its target SPI1 and CEBPB. Conclusion: Our results suggest that activating mutation of FLT3 in AML can lead, through the induction of JUN, to an increased expression of miR-155, which then causes down-regulation of SPI1 and CEBPB and consequently may causes block of myeloid differentiation. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:883 / 896
页数:14
相关论文
共 50 条
  • [21] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Masamichi Mori
    Naoki Kaneko
    Yoko Ueno
    Masaki Yamada
    Ruriko Tanaka
    Rika Saito
    Itsuro Shimada
    Kenichi Mori
    Sadao Kuromitsu
    Investigational New Drugs, 2017, 35 : 556 - 565
  • [22] "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
    Knight, Tristan E.
    Edwards, Holly
    Meshinchi, Soheil
    Taub, Jeffrey W.
    Ge, Yubin
    CANCERS, 2022, 14 (14)
  • [23] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
    Wang, Eunice S.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
  • [24] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Mori, Masamichi
    Kaneko, Naoki
    Ueno, Yoko
    Yamada, Masaki
    Tanaka, Ruriko
    Saito, Rika
    Shimada, Itsuro
    Mori, Kenichi
    Kuromitsu, Sadao
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 556 - 565
  • [25] Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
    Numan, Yazan
    Abdel Rahman, Zaid
    Grenet, Justin
    Boisclair, Stephanie
    Bewersdorf, Jan Philipp
    Collins, Cailin
    Barth, Dylan
    Fraga, Martina
    Bixby, Dale L.
    Zeidan, Amer M.
    Yilmaz, Musa
    Desai, Pankil
    Mannis, Gabriel
    Deutsch, Yehuda E.
    Abaza, Yasmin
    Dinner, Shira
    Frankfurt, Olga
    Litzow, Mark
    Al-Kali, Aref
    Foran, James M.
    Sproat, Lisa Z.
    Jovanovic, Borko
    Daver, Naval
    Perl, Alexander E.
    Altman, Jessica K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : 322 - 328
  • [26] Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia
    Nguyen, Le Xuan Truong
    Zhang, Bin
    Hoang, Dinh Hoa
    Zhao, Dandan
    Wang, Huafeng
    Wu, Herman
    Su, Yu-Lin
    Dong, Haojie
    Rodriguez-Rodriguez, Sonia
    Armstrong, Brian
    Ghoda, Lucy Y.
    Perrotti, Danilo
    Pichiorri, Flavia
    Chen, Jianjun
    Li, Ling
    Kortylewski, Marcin
    Rockne, Russell C.
    Kuo, Ya-Huei
    Khaled, Samer
    Carlesso, Nadia
    Marcucci, Guido
    LEUKEMIA, 2021, 35 (08) : 2285 - 2298
  • [27] Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia
    Le Xuan Truong Nguyen
    Bin Zhang
    Dinh Hoa Hoang
    Dandan Zhao
    Huafeng Wang
    Herman Wu
    Yu-Lin Su
    Haojie Dong
    Sonia Rodriguez-Rodriguez
    Brian Armstrong
    Lucy Y. Ghoda
    Danilo Perrotti
    Flavia Pichiorri
    Jianjun Chen
    Ling Li
    Marcin Kortylewski
    Russell C. Rockne
    Ya-Huei Kuo
    Samer Khaled
    Nadia Carlesso
    Guido Marcucci
    Leukemia, 2021, 35 : 2285 - 2298
  • [28] SHIP1 is targeted by miR-155 in acute myeloid leukemia
    Xue, Hua
    Hua, Luo-Ming
    Guo, Ming
    Luo, Jian-Min
    ONCOLOGY REPORTS, 2014, 32 (05) : 2253 - 2259
  • [29] FLT3 Inhibitors for Treating Acute Myeloid Leukemia
    Hassanein, Mona
    Almahayni, Muhamad H.
    Ahmed, Syed O.
    Gaballa, Sameh
    El Fakih, Riad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (10): : 543 - 549
  • [30] FLT3 inhibitors for the treatment of acute myeloid leukemia
    Metzelder S.
    Röllig C.
    best practice onkologie, 2018, 13 (4) : 182 - 190